Evidence map›Paper›PMID 35663021›Full record

ArticleiScience2022

The

Carolina Herrera, Mackenzie L Cottrell, John Prybylski, Angela D M Kashuba, Ronald S Veazey, Javier García-Pérez, Natalia Olejniczak, Clare F McCoy, Paul Ziprin, Nicola Richardson-Harman and 3 more

Open access · goldAbstract read
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Carolina HerreraSection of Virology, Faculty of Medicine, St. Mary's Campus, Imperial College London, UK.
Mackenzie L CottrellUniversity of North Carolina at Chapel Hill, UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, Chapel Hill, NC, USA.
John PrybylskiUniversity of North Carolina at Chapel Hill, UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, Chapel Hill, NC, USA.
Angela D M KashubaUniversity of North Carolina at Chapel Hill, UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, Chapel Hill, NC, USA.
Ronald S VeazeyTulane National Primate Research Center, Tulane University School of Medicine, Covington, LA, USA.
Javier García-PérezAIDS Immunopathology Unit. National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Natalia OlejniczakSection of Virology, Faculty of Medicine, St. Mary's Campus, Imperial College London, UK.
Clare F McCoySchool of Pharmacy, Medical Biology Centre, Queen's University of Belfast, Belfast, UK.
Paul ZiprinDepartment of Surgery and Cancer, St Mary's Hospital, Imperial College London, UK.
Nicola Richardson-HarmanAlpha StatConsult, LLC, Damascus, MD, USA.
José AlcamiAIDS Immunopathology Unit. National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Karl R MalcolmSchool of Pharmacy, Medical Biology Centre, Queen's University of Belfast, Belfast, UK.
Robin J ShattockSection of Virology, Faculty of Medicine, St. Mary's Campus, Imperial College London, UK.
Imperial College London · GBUniversity of North Carolina at Chapel Hill · USInstituto de Salud Carlos III · ESQueen's University Belfast · GBSt Mary's Hospital · GBTulane University · US

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Mucosal tissue explants as surrogates for in vivo efficacy of microbicidesR21AI094515 · NIAID · IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE · PI HERRERA, CAROLINA, SHATTOCK, ROBIN J · 2011 to 2012
$352k
NIAID NIH HHS R21 AI094515NIH HHS P51 OD011104
6 · The paper itself

Abstract

Non-human primates (NHP) are widely used for the pre-clinical assessment of antiretrovirals (ARVs) for HIV treatment and prevention. However, the utility of these models is questionable given the differences in ARV pharmacology between humans and macaques. Here, we report a model based on

Indexed as

Biological sciencesBiological sciences research methodologiesImmunologyNatural sciencesToxicology

Identifiers

PMID35663021
PMCPMC9157191
OpenAlexW4280569490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.